BRIEF-Cytokinetics expects results from VITALITY-ALS in 2H 2017
August 17, 2016 at 07:54 AM EDT
* Cytokinetics completes enrollment in VITALITY-ALS, phase 3 clinical trial of Tirasemtiv in patients with ALS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.